Heron Therapeutics Inc - HRTX Enterprise Value-to-Sales Ratio

Official company branding of Heron (HRTX)

Stable demand for hospital drugs ensures high macro-resilience for Heron Therapeutics (HRTX). The current EV/Sales ratio reflects the company's enterprise value relative to revenue excluding debt, fixing the metric at 1076.64. Growth is driven by the integration of analgesics into medical protocols. Heron Therapeutics is pursuing its path to profitability independently by expanding distribution through partnerships with logistics operators.

Heron Therapeutics, Inc. (HRTX): Company Value to Revenue from 11/23/2025 to 11/20/2026

Heron Therapeutics, Inc. - analytical breakdowns and key metrics (HRTX)

- price and consensus price forecast:
- cash balance and cash flow data:
Fundamental company valuation:HRTX, Heron Therapeutics Inc
Manufactured products of herontx.com

This indicator determines the market value of the business, accounting for net debt per unit of generated revenue. The EV/Sales ratio trend allows analysts to filter out price volatility and identify real trends in asset revaluation by institutional capital. This metric shows how much an investor pays for current turnover, excluding the impact of the debt load. For Heron Therapeutics (HRTX), an increase in this ratio may reflect market expectations regarding the implementation of robotic packaging and the digitalization of logistics. Warehouse automation reduces costs, potentially increasing the efficiency of every unit of revenue.